GlobalData has suggested that Ohtuvayre could have a transformative role to play in the management of COPD patients who are prone to exacerbations, sudden flare-ups in symptoms that signal the ...

Ohtuvayre showed significant improvement in lung function by 12 weeks. Follow-up analyses showed that Ohtuvayre had long-term ...

Verona Pharma stock hit a record high Thursday on continued enthusiasm for its newly launched COPD treatment, Ohtuvayre.

Verona Pharma (VRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from ...

H.C. Wainwright analyst increased the price target on shares of Verona Pharma (NASDAQ:VRNA) to $60 from the previous target of $42, maintaining a Buy rating on the shares.

9. Ohtuvayre (ensifentrine) for COPD: Approved June 26, the inhaled medication is the first new type of maintenance COPD drug in over a decade. 10. Wakix (pitolisant) for pediatric narcolepsy ...

Consensus for Q4 revenue is $12.94M. Expects to report cash and cash equivalents at December 31, 2024, of $400M vs. $271.8M a year ago. “2024 ...

“These trends reinforce our belief that Ohtuvayre’s bronchodilator and non-steroidal anti-inflammatory activity can re-define the COPD treatment paradigm,” CEO David Zaccardelli remarke ...

with more doctors adding Ohtuvayre to a new patient’s regimen as they come in for scheduled visits and report a lack of control of their COPD symptoms, the firm added.

To participate, please dial one of the following numbers and ask to join the Verona Pharma call: +1- Ohtuvayre is indicated for the maintenance treatment of COPD allowing for broad use in COPD ...